Aspergillosis is a condition causing serious morbidity and mortality in captive penguins and other bird species. It can be treated with antifungal drugs, such as voriconazole.
be exposed to low levels of spores without developing disease, but disease frequently occurs in stressed or debilitated birds. Stressors include substandard air quality, poor ventilation, overcrowding, excessive environmental heat or cold and social incompatibility (Filho et al., 2015; McMillian & Petrak, 1989; Phalen, 2000; Redig, 2000; Verstappen & Dorrestein, 2005; Wallace, 2015) . Aspergillus spp. are transmitted by air, and in birds, they mainly infect the pulmonary parenchyma and air sac membranes (Seyedmousavi et al., 2015) .
In affected birds, chronic aspergillosis most commonly exhibits as voice change, anorexia, biliverdinuria, lethargy or depression, dyspnea, and emaciation. Occasionally, ataxia or paralysis can occur if the central nervous system is affected (Dahlhausen, 2006) . Chronic cases of aspergillosis in captive birds have a persistent clinical course that can last weeks or months (Neumann, 2016) . In contrast, acute cases, which are caused by high levels of fungal spores and/ or severe immunosuppression, progress very quickly and penguins are often dead within 24-48 hr (Kearns & Loudis, 2003) .
Voriconazole
a is a triazole antifungal drug effective against a broad spectrum of fungi, including Aspergillus species (Antonissen & Martel, 2018) . Voriconazole acts by inhibiting fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, thus interrupting an important stage in fungal ergosterol biosynthesis (Antonissen & Martel, 2018) . In vitro, voriconazole demonstrates high fungicidal activity against Aspergillus spp. (Sabino et al., 2016) . Efficacy and exposure are positively correlated, with an AUC/MIC ratio of >25 established as the target for acceptable clinical outcomes in mice (Andes, Marchillo, Stamstad, & Conklin, 2003) . Clinical breakpoints for voriconazole in Aspergillus spp. isolates from birds are not established; however, aspergillosis in both humans and birds is usually caused by Aspergillus fumigatus (Seyedmousavi et al., 2015) . Instead of a clinical breakpoint, the epidemiological cutoff (ECOFF) value may be used for veterinary species. The ECOFF for voriconazole for
Aspergillus fumigatus has been established as a MIC of 1.0 mg/L (EUCAST, 2018).
The pharmacokinetics of voriconazole have been reasonably well-studied in different bird species including red-tailed hawks (Gentry et al., 2014; Parsley, Tell, & Gehring, 2017) , several species of parrots (Flammer et al., 2008; Sanchez-Migallon Guzman et al., 2010) , chickens (Burhenne, Haefeli, Hess, & Scope, 2008) , and Japanese quail (Souza, Redig, & Cox, 2017; Tell et al., 2010) . To date, only one study assessed voriconazole pharmacokinetics in penguins (Hyatt, Wiederhold, Hope, & Stott, 2017 ). Hyatt and co-workers studied the pharmacokinetics of orally administered voriconazole in African penguins (Spheniscus demersus) as a single-dose and a once-daily repeated dosage regimen. The most striking findings were the fast absorption of voriconazole after oral administration in penguins (T max 0.4 hr) compared to voriconazole absorption in other bird species studied (only studies with fasted animals considered) and the prolonged elimination half-life in penguins receiving the daily dosage regimen (T ½ 10.9 hr) compared to elimination half-lives in other bird species (T ½ 1.0-1.7 hr). 
| MATERIAL S AND ME THODS

| Animals
| Study 1-3
Fifteen adult captive Magellanic penguins (Spheniscus magellanicus, seven females and eight males, ages 2-11 years) at the San Francisco Zoo, with body weights ranging from 3.70 kg to 6.69 kg (mean 4.69 kg ± 0.71 kg) were used in this study. The sex of the birds was determined by DNA testing. All birds were considered healthy based on physical examination and evaluation of medical history. Birds were moved from their normal exhibit 48 hr prior to initiation of the study and housed in temporary holding pens. They had access to water at all times other than the first 2 hr of the study period. Birds were fed according to their normal schedule on the day prior to the study initiating. On the day of the study, the morning feeding was replaced with a single medicated fish, and normal feeding was resumed at 7.5 hr following drug administration.
| Clinical case
An adult (8.5 years, bodyweight on presentation 3.33 kg) male penguin presented with a recurrent cough and weight loss over 6 weeks. Aspergillus fumigatus was isolated from a bronchial wash and oral treatment with voriconazole was initiated. He was held in a smaller pen with his mate during treatment periods when he was ill and not eating consistently. During these times, he had access to water and a normal feeding schedule.
All procedures relating to this study were performed in strict accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of California, Davis.
| Drug formulations
For the three study parts, oral voriconazole powder a was reconstituted according to manufacturer's instructions, by adding 11.5 ml of deionized ultrafiltered water to 11.295 g powder to obtain a suspension with a final voriconazole concentration of 40 mg/ml. Due to limitations regarding drug administration options in captive animals, the voriconazole suspension was injected into the coelomic cavity of a herring and fed to the penguin. A 25-gauge needle was used for injecting the fish with voriconazole suspension to minimize drug loss from the injection site.
For the clinical case, the formulation of voriconazole was compounded from five voriconazole tablets (50 mg) that were crushed using a mortar and pestle and suspended in 10 ml of sterile water with a targeted concentration of 25 mg/ml. New suspension was prepared every 2 weeks. 
| Study 2
Each penguin received a single oral dose of voriconazole (dosage = 5 mg voriconazole per kg body weight) in a herring, and samples were collected before voriconazole administration (blank), and 0.5, 1, 2, 5, 8, 12, and 24 hr postadministration as described above.
The blood was processed as described above, and the data were pooled for each time point.
| Study 3
Each penguin received a single oral dose of voriconazole (dosage = 5 mg voriconazole per kg body weight) in a herring, and samples were collected before voriconazole administration (blank), and 0.5, 1, 2, 5, 8, 12, 24, 32, 48, 56, 72 and 96 hr postadministration as described above. Five penguins were sampled at each time point, and each individual was only bled at four of the time points in order to minimize the handling of the animals. The blood was processed as described above, and the data were pooled for each time point. 
| Clinical case
| Sample analysis: ultraperformance liquid chromatography
Voriconazole plasma concentrations were measured using an ultra performance liquid chromatography (UPLC) method coupled with ultraviolet (UV)-detection. Plasma samples (250 μl)
were prepared on C18 solid-phase extraction cartridges 
| Compartmental analysis
A compartmental pharmacokinetic model using nonlinear mixedeffects regression as implemented in the commercially available software program Phoenix NLME ® (Certara e USA, Princeton, NJ) was fit to the plasma drug concentration-time data. The fits of both oneand two-compartment structural models with and without saturable clearance (Michaelis-Menten) were explored. Additive, multiplicative and power (Poisson) models were explored for the residual error.
Bodyweight was explored as a covariate for total body clearance and apparent volume of distribution. Since the bioavailability of the oral administration in fish is unknown, the total body clearance and apparent volume of distribution are both in relation to bioavailability. TA B L E 1 (Continued) (Continues) to information loss and is therefore considered the better model to describe the collected data (Akaike, 1974) . Since there is no official cutoff value to establish whether a certain increase or decrease in AIC is significant, it is important take biological/physiological processes in the study population into consideration when choosing the most appropriate pharmacokinetic model to describe and predict pharmacokinetics. Therefore, also visual inspection of plots of the observed vs. predicted concentration data and visual inspection of the plot of residuals vs. time (an error model that resulted in a consistent spread of residuals around an average of zero was chosen) were used to assess model performance. where C is the voriconazole concentration in the plasma, A is the amount of drug in the body, Vd is the apparent volume of distribution (in relation to bioavailability), k a is the absorption rate constant, A a is the amount of drug at the site of administration, CL is the total body clearance (in relation to bioavailability), and t is time.
| First-order elimination model
| Population-based first-order elimination model
The model was refined since interindividual variability was high and was incorporated into the model using Equations (3) and (4) where i denotes the value of the parameter for the individual, tv denotes the typical value of the parameter for the population, η denotes the parameter that adjusts the typical value for the population to each individual, and dCL dose adjusts the typical value for the population to account for doselevel (low = 1 and high = 0). where V max denotes maximal clearance rate, and k m denotes the drug concentration at which clearance is 50% of maximum.
| Michaelis-menten elimination model
| Population-based michaelis-menten elimination model
Interindividual variability was incorporated into the model using Equations (7) through 10 with bodyweight as a covariate.
where i denotes the value of the parameter for the individual, tv denotes the typical value of the parameter for the population, η denotes the parameter that adjusts the typical value for the population to each individual, and dVdweight denotes the parameter that adjusts the value of the volume of distribution for bodyweight.
| Simulation and model validation
The final two models (the first-order elimination kinetic model and 
| RE SULTS
The measured plasma voriconazole concentration vs. time data are given in Figure 1 , showing a steeper slope for the terminal elimination
phase in the profiles with the lower concentrations (corresponding to the animals that were given the 2.5 mg/kg dose) compared to the profiles with the higher concentrations (corresponding to the animals that were given the 5 mg/kg dose). Plasma concentrations were above the targeted MIC of 1.0 μg/ml for susceptible Aspergillus fumigatus (EUCAST, 2018) only at the 2 hr sample time after the 2.5 mg/kg dose, whereas concentrations remained above this level for up to 56 hr after the administration of the 5 mg/kg dose. The noncompartmental pharmacokinetic parameters calculated for the two different doses using naïve pooling of the sparse data are summarized in Table 2 . The parameter values for the initial (no covariates) and final (dose level a covariate of CL) versions of the first-order and Michaelis-Menton elimination models are given in Tables 3 and 4 .
| Comparison of pharmacokinetic models
The pharmacokinetic model that incorporated the Michaelis-Menten Table 4 .
| Simulations and model validation
The pharmacokinetic model with Michaelis-Menten elimination kinetics predicted drug accumulation and plasma voriconazole concentrations that continued to rise over time. Figure 3a 
| D ISCUSS I ON
The pharmacokinetics of voriconazole have been described in various veterinary species, but this is the first pharmacokinetic study performed in Magellanic penguins. Also, this study compared two pharmacokinetic compartmental models to describe the pharmacoki- Lower-than-expected concentrations following repeated and/or long-term administration, as was the case with the penguin with aspergillosis in this study, have also been observed in African Grey parrots, Hispaniolan Amazon parrots, and pigeons (Beernaert et al., 2009; Flammer et al., 2008; Sanchez-Migallon Guzman et al., 2010) .
A possible explanation for these observations is that metabolizing enzymes in these birds became induced after long-term administration, increasing the body's capacity to eliminate the drug and therefore converting an initially saturable process to a first-order one. It is also possible that CYP enzymes of another subfamily were able to take over part of the metabolism of voriconazole; however, both these hypotheses have never been studied in penguins, or in Notes. CL, total body clearance; CV%, Coefficient of variation (measure of accuracy with which tv is predicted); dVdweight, fixed effect to explain how interindividual variability in volume of distribution is related to body weight; IIV, interindividual variability (variance of η's); k a , absorption rate constant; NA, Not applicable; tv, typical value of the parameter for the population; V, apparent volume of distribution a V and CL values are confounded by unknown bioavailability of voriconazole following oral administration.
TA B L E 4
Parameter values for the one-compartment model with first-order absorption and nonlinear elimination with or without bodyweight as a covariate for volume of distribution other bird species. It is known that voriconazole is primarily metabolized by CYP2C19 (of which polymorphisms are known to exist in humans) and to a lesser extent by CYP2C9 and CYP3A4 in humans (Pfizer, Vfend package insert). For Magellanic penguins, it is unknown whether such polymorphisms or other variations in CYP enzyme profiles exist; however, there is evidence for differences in CYP expression between other bird and penguin species. A study by Almeida and co-workers (Almeida et al., 2016) on the genome of a large variety of bird species studying the presence of metabolic enzymes of the CYP2 family on a DNA level revealed a striking difference in the profile between Adelie penguins and Emperor penguins, even though both species live in the same environmental conditions and have a comparable diet. Adelie penguins appeared to have a broad spectrum of CYP2 enzymes, but lacking sufficient CYP2C enzymes, while the Emperor penguin only had three out of twelve CYP2 isoforms tested in the study. Since such differences are found between those two species of penguins, it cannot be ruled out that specific CYP enzymes are also lacking or expressed to a different extent in Magellanic penguins.
Metabolic differences may not only exist between bird/penguin species but also between individuals of the same species. These differences may result in drug toxicity in individuals due to large differences in achieved voriconazole plasma concentrations. Twentyfour cases of suspected voriconazole toxicity in six species of penguin have been reported by Hyatt and co-workers (Hyatt et al., 2015) . Clinical signs of toxicity included anorexia, abnormal behavior (lethargy, changes in mentation, depression, isolating self, staring off into the distance), or neurologic signs (weakness, ataxia, paresis, apparent changes in vision, seizure-like activity, and seizures) in penguins and elevated liver enzymes and bile acids in other birds (Hyatt et al., 2015) . In the Hyatt et al. (2015) , With regard to assessing both voriconazole effective doses and risk of possible toxic effects, the formulation used for drug administration in penguins has to be considered. Although the manufacturer instructs to avoid administration of voriconazole with high-fat food due to a significant reduction of C max and AUC (34% and 24%
for tablets and 58% and 37% reduction for the oral suspension, respectively), voriconazole is usually administered to penguins in fish to minimize stress due to handling of the animals. Also, crushed tablets in water are often used instead of the suspension for oral administration due to economic reasons. The manufacturer states that bioequivalence was established between voriconazole tablets and the 40 mg/ml of suspension for oral administration when the same dose of voriconazole in mg was administered orally to humans (Pfizer, Vfend package insert). However, this bioequivalence seems no longer present when the drug is administered together with food (since there is a different effect on C max and AUC for the tablets compared to the oral solution). With regard to the fish feeding, Hyatt and co-workers (Hyatt et al., 2017) tested both oral gavage and administration of voriconazole in fish to African penguins. They describe a mean lag phase of 1.53 hr in the pharmacokinetic concentrationtime profile in penguins dosed with voriconazole in fish, compared to penguins dosed by oral gavage. Furthermore, in the same study the plasma concentrations measured on day 2 of the multiple dose study where already much higher (3.36 μg/ml 2 hr postdose) than the mean plasma C max (1.89 μg/ml at 0.4 hr postdose) measured in the singledose study in the penguins receiving oral gavage. Therefore, the influence of the fish was apparently not significantly high to strongly reduce the amount absorbed after oral administration, although part of this may have been obscured by the long elimination half-life of voriconazole (10.9 hr) measured in these penguins.
In conclusion, the pharmacokinetic models presented in this study accurately predict saturation elimination processes after a single dose of voriconazole and predict the switch in elimination of voriconazole to a first-order process during long-term treatment.
Given the possible high interindividual variability in pharmacokinetics and the lack of information regarding metabolic pathways in 
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